These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37235686)

  • 1. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study.
    Tardieu M; Cudejko C; Cano A; Hoebeke C; Bernoux D; Goetz V; Pichard S; Brassier A; Schiff M; Feillet F; Rollier P; Mention K; Dobbelaere D; Fouilhoux A; Espil-Taris C; Eyer D; Huet F; Walther-Louvier U; Barth M; Chevret L; Kuster A; Lefranc J; Neveu J; Pitelet G; Ropars J; Rivier F; Roubertie A; Touati G; Vanhulle C; Tardieu E; Caillaud C; Froissart R; Champeaux M; Labarthe F; Chabrol B
    Eur J Neurol; 2023 Sep; 30(9):2828-2837. PubMed ID: 37235686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
    Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
    Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
    PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
    Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
    Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort.
    Pfrimmer C; Smitka M; Muschol N; Husain RA; Huemer M; Hennermann JB; Schuler R; Hahn A
    J Neuromuscul Dis; 2024; 11(1):167-177. PubMed ID: 38043017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.
    Markic J; Polic B; Stricevic L; Metlicic V; Kuzmanic-Samija R; Kovacevic T; Ivkosic IE; Mestrovic J
    Wien Klin Wochenschr; 2014 Feb; 126(3-4):133-7. PubMed ID: 24337590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
    Hsueh CY; Huang CY; Yang CF; Chang CC; Lin WS; Cheng HL; Wu SL; Cheng YF; Niu DM
    Orphanet J Rare Dis; 2021 Aug; 16(1):348. PubMed ID: 34353347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
    Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
    Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.